A double-blind, randomized, controlled phase III study to assess the prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.

Trial Profile

A double-blind, randomized, controlled phase III study to assess the prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs GSK 208141 (Primary) ; Hepatitis A vaccine
  • Indications Hepatitis A; Herpes genitalis
  • Focus Registrational; Therapeutic Use
  • Acronyms HerpeVac
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Jan 2012 Results published in the New England Journal of Medicine.
    • 29 Sep 2011 GlaxoSmithKline as company and lead trial centre added; and actual patient number is 8323 as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Actual end date (August 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top